High-dose hepatitis B immunoglobulin therapy in hepatocellul

发布时间：2021-11-14 13:52

　　AIM: To investigate the impact of high-dose hepatitis B immunoglobulin（HBIG） on hepatocellular carcinoma（HCC） and hepatitis B virus（HBV） recurrence and overall survival after living donor liver transplantation（LDLT）.METHODS: We investigated 168 patients who underwent LDLT due to HCC, and who were HBV-DNA/hepatitis B e antigen（HBe Ag）-positive, from January 2008 to December 2013. After assessing whether the patients met the Milan criteria, they were assigned to the low-dose HBIG group and high-do... 

【文章来源】：World Journal of Gastroenterology. 2016,22(14)

【文章页数】：10 页


本文编号：3494756